Cover Image

PARP inhibition in BRCA2-mutated prostate cancer

Defects in DNA repair genes are increasingly recognized as a defining molecular feature of a subset of patients with prostate cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to have clinical activity in this subgroup, but other compounds including platinum also warrant explora...

Full description

Saved in:
Bibliographic Details
Main Authors: Nientiedt, Cathleen (Author) , Tolstov, Yanis (Author) , Volckmar, Anna-Lena (Author) , Endris, Volker (Author) , Haberkorn, Uwe (Author) , Jäger, Dirk (Author) , Stenzinger, Albrecht (Author) , Hohenfellner, Markus (Author) , Grüllich, Carsten (Author) , Duensing, Stefan (Author)
Format: Article (Journal) Editorial
Language:English
Published: 2017
In: Annals of oncology
Year: 2016, Volume: 28, Issue: 1, Pages: 189-191
ISSN:1569-8041
DOI:10.1093/annonc/mdw445
Online Access:Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdw445
Verlag, Volltext: https://academic.oup.com/annonc/article/28/1/189/2669812
Get full text
Author Notes:C. Nientiedt, Y. Tolstov, A.-L. Volckmar, V. Endris, D. Bonekamp, U. Haberkorn, D. Jäger, H. Sültmann, A. Stenzinger, M. Hohenfellner, C. Grüllich, S. Duensing
Description
Summary:Defects in DNA repair genes are increasingly recognized as a defining molecular feature of a subset of patients with prostate cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to have clinical activity in this subgroup, but other compounds including platinum also warrant exploration. We report here the remarkable clinical course of a patient with a germline BRCA2 mutation treated with the PARP inhibitor olaparib.
Item Description:Published online 29 September 2016
Gesehen am 19.07.2018
Physical Description:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdw445

Similar Items